Related Experiment Video
Updated: Jan 19, 2026

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
Published on: September 16, 2011
LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy
1Institute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Vagelos College for Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Abstract:
In this issue of Cancer Cell, Parvin and colleagues identify the expression of LMO2 as a biomarker for DNA repair defects in lymphomas. Using isogenic cell lines and xenografts, the authors show that expression of LMO2 predicts sensitivity to PARP inhibition, especially in combination with genotoxic therapy.
Related Concept Videos
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
10:22Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
08:25Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:23Chronic Constriction of the Sciatic Nerve and Pain Hypersensitivity Testing in Rats
08:25Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:14Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

